Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial by Sweet, K, Dasgupta, B, De Vries, D, Gourley, I, Hsu, B, Loza, M, Taylor, P

Dislocations behavior in highly mismatched III-Sb growth and their impact on the fabrication of top-down n + InAs/p + GaSb nanowire tunneling devices by El Kazzi, S, Alian, A, Hsu, B, Favia, P, Merckling, C, Lu, W, del Alamo, JA, Collaert, N

Get full text

Efficacy and safety of monotherapy with sirukumab, an anti-IL-6 cytokine monoclonal antibody, compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid... by Taylor, P, Schiff, M, Wang, Q, Jiang, Y, Kurrasch, R, Daga, S, Rao, R, Hsu, B, Tak, P

Efficacy and safety of monotherapy with sirukumab compared to adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-... by Taylor, P, Schiff, M, Wang, Q, Jiang, Y, Zhuang, Y, Kurrasch, R, Daga, S, Rao, R, Tak, P, Hsu, B

Careful stoichiometry monitoring and doping control during the tunneling interface growth of an n + InAs(Si)/p + GaSb(Si) Esaki diode by El Kazzi, S., Alian, A., Hsu, B., Verhulst, A.S., Walke, A., Favia, P., Douhard, B., Lu, Wenjie, del Alamo, Jesus A, Collaert, N., Merckling, C.

Get full text